<DOC>
	<DOCNO>NCT00291915</DOCNO>
	<brief_summary>Evaluation two treatment modality early potentially severe early arthritis ( Methotrexate alone combination adalimumab )</brief_summary>
	<brief_title>Multicenter Randomized Prospective Trial Comparing Methotrexate Alone Combination With Adalimumab Early Arthritis</brief_title>
	<detailed_description>Patients : early ( less 6 month ) , active ( DAS &gt; 5.2 ) , potentially severe ( Leiden score &gt; 6 ) Study design:12 month , prospective , randomize , open Study treatment : Methotrexate weekly dose 0.3mg/kilo alone combination adalimumab 40 mg every week Outcome measure : DAS 12 month</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Early Active Potentially severe arthritis contra indication methotrexate anti TNF</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2006</verification_date>
	<keyword>early arthritis , methotrexate , adalimumab</keyword>
</DOC>